98%
921
2 minutes
20
Objective: This study aimed to systematically map available evidence on menopause-related knowledge, symptoms and management in low and middle-income countries (LMICs) and identify critical gaps to inform research and policy.
Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Review (PRISMA-ScR) guidelines, the MEDLINE, EMBASE, CINAHL and Scopus databases were searched for studies published between 2000 and 2024. Eligible studies were those that reported on menopause-related knowledge, symptom prevalence or management in LMICs. Data were extracted and synthesised descriptively and thematically.
Results: From 10,758 records, 252 studies from 41 LMICs were included. Most were cross-sectional (85%) and relied on non-probability sampling (62%), with only 4% being nationally representative. Menopause classification methods were often inconsistent, with only 17.5% of studies using the Stages of Reproductive Aging Workshop (STRAW) +10 or World Health Organization (WHO) criteria. National-level data on age at menopause are lacking across all LMICs. The prevalences of vasomotor symptoms, joint pain and sexual concerns were comparable with high-income countries. However, data on the severity and burden of symptoms were scarce. Knowledge about menopause and menopausal hormone therapy (MHT) was poor, especially in low-income and rural settings. Cultural stigma, misconceptions and healthcare provider knowledge gaps contributed to low uptake of evidence-based menopause care. MHT use was consistently low, with women predominantly using traditional remedies. Provider hesitancy, lack of training and structural health system barriers were key limitations in service delivery.
Conclusions: Despite a growing population of postmenopausal women, menopause remains a neglected health issue across LMICs. There is an urgent need to integrate menopause into reproductive and non-communicable disease policies, invest in provider education and ensure equitable access to evidence-based menopause care, including MHT, for women in LMICs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/13697137.2025.2509254 | DOI Listing |
Climacteric
September 2025
Gynecology Discipline, Obstetrics and Gynecology Department, University of São Paulo School of Medicine, São Paulo, Brazil.
Objective: Social media is an increasingly relevant tool for health education, enabling information exchange, promoting autonomy and supporting informed decision-making. This study introduces Menopausando, a predominantly Portuguese-language digital platform designed to support women during menopausal transition and postmenopause.
Method: This cross-sectional study has been carried out in the Gynecology Discipline, São Paulo University, Brazil, since 2019.
Cureus
August 2025
Internal Medicine, Khwaja Yunus Ali Medical College, Sirajganj, BGD.
Endometrial carcinoma is one of the most common gynecologic cancers worldwide. The condition typically occurs after menopause; however, young women under the age of 40 years can also be diagnosed with the disease. Providers may delay diagnosis in young patients due to nonspecific presentation or low clinical suspicion.
View Article and Find Full Text PDFMedicine (Baltimore)
September 2025
Obstetrics and Gynecology, Civil Aviation General Hospital, Beijing, China.
This study aims to elucidate the relationship between the triglyceride-glucose index (TyG) index and perimenopausal abnormal uterine bleeding (AUB) risk. A total of 306 patients diagnosed with perimenopausal AUB at our hospital between January 2022 and December 2023 were enrolled. Using a TyG index cutoff of 0.
View Article and Find Full Text PDFAccessory cavitated uterine malformation is a rare congenital anomaly of Müllerian duct development that typically affects younger women of reproductive age. The most common symptoms include chronic cyclic pelvic pain and severe dysmenorrhea, although diagnosis is frequently delayed owing to its rarity, multiple differential diagnoses, and low patient awareness. This report describes the case of a perimenopausal woman with accessory cavitated uterine malformation.
View Article and Find Full Text PDFJAMA Intern Med
September 2025
Bayer CC AG, Basel, Switzerland.
Importance: There is an unmet need for long-term, safe, effective, and hormone-free treatments for menopausal symptoms, including vasomotor symptoms (VMS) and sleep disturbances.
Objective: To evaluate the 52-week efficacy and safety of elinzanetant, a dual neurokinin-targeted therapy, for treating moderate to severe VMS associated with menopause.
Design, Setting, And Participants: OASIS-3 was a double-blind, placebo-controlled, randomized phase 3 clinical trial that was conducted at 83 sites in North America and Europe from August 27, 2021, to February 12, 2024, and included postmenopausal women aged 40 to 65 years who were seeking treatment for moderate to severe VMS (no requirement for a minimum number of VMS events per week).